Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Cushing’s Syndrome Diagnostics and Therapeutics Market Size & Share 2026-2035
Report ID: GMI15235
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Cushing’s Syndrome Diagnostics and Therapeutics Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Cushing's Syndrome Diagnostics and Therapeutics Market Size
The Cushing's syndrome diagnostics and therapeutics market was valued at USD 422.9 million in 2025, is projected to reach USD 463.0 million in 2026, and is expected to grow at a 9.2% CAGR (2026–2035) to reach USD 1.02 billion by 2035. The market encompasses biochemical testing, specialist laboratory services, and pharmacotherapies used from clinical suspicion through long-term management of endogenous and exogenous Cushing's syndrome.
Cushing’s Syndrome Diagnostics and Therapeutics Market Key Takeaways
Market Leader: Corcept Therapeutics led with over 15% market share in 2025.
Leading Players: Top 5 players in this market include Corcept Therapeutics, Recordati, Novartis, Thermo Fisher Scientific, ESTEVE Pharmaceuticals, which collectively held a market share of 35% in 2025.
The Cushing's syndrome diagnostics and therapeutics market is being reshaped by improved biochemical confirmation, established rare-disease treatment channels, and broader commercial interest in selective cortisol-modulating therapies. Therapeutics remains the principal revenue pool, while higher-specificity testing is improving the transition from symptom recognition to specialist-led intervention.
GMI Analyst View
Based on input from industry leaders, the Cushing's syndrome diagnostics and therapeutics market is tracking toward USD 936.2 million in 2034, reflecting an uninterrupted compound expansion driven by Therapeutics revenue momentum rather than any single pricing event. This near-decade trajectory signals that commercial-stage agent performance - rather than new-product approval timing - has become the primary structural force shaping the market's medium-term outlook.
Cushing's Syndrome Diagnostics and Therapeutics Market Trends, Growth Drivers & GMI Forecast Outlook
Market expansion depends on converting a difficult clinical presentation into earlier confirmed diagnoses and sustained treatment episodes. Product innovation, assay sophistication, and specialist referral capacity support demand, while reimbursement friction and demanding regulatory evidence requirements continue to shape how quickly that demand becomes commercial revenue.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Cushing's syndrome often presents through metabolic, psychiatric, cardiovascular, and musculoskeletal symptoms that can initially be managed as more common conditions. This makes testing pathways, specialist referral discipline, and assay selection commercially consequential: each improvement in diagnostic confidence increases the share of suspected patients who progress to confirmatory testing and ultimately to an active treatment pathway.
Orphan-drug incentives also matter beyond exclusivity. They help make highly specialized clinical programs investable despite limited patient populations and heterogeneous disease etiologies. The expanded FDA indication for Isturisa illustrates how regulatory progress can broaden the addressable clinical setting for an established therapy, while clofutriben's development activity indicates continuing interest in differentiated cortisol-modulating approaches [3]U.S. Food and Drug Administration. "Approval Letter - NDA 212801/S-003, Isturisa (osilodrostat)." accessdata.fda.gov[5]Sparrow Pharmaceuticals, Inc. "Sparrow Pharmaceuticals Announces Completion of Phase 2 Trial and FDA Orphan Drug Designation of Clofutriben for Endogenous Cushing's Syndrome." businesswire.com.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
High acquisition costs affect more than affordability. They make access dependent on prior authorization, specialist pharmacy distribution, and the ability of health systems to absorb rare-disease treatment budgets. These requirements favor organized payer markets and specialist centers while narrowing commercial participation in settings where patients bear a larger share of treatment costs.
Diagnostic delay compounds this constraint because delayed confirmation shortens the period during which patients receive disease-specific management. A meta-analysis found that diagnosis is commonly delayed across Cushing's syndrome subtypes, reinforcing the need for clearer referral pathways and reliable biochemical workups [7]Rubinstein G, Osswald A, Hoster E, et al. "Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients." academic.oup.com. Regulatory uncertainty can further limit market entry when sponsors must establish benefit across clinically diverse patient populations and support long-term risk management.
GMI Analyst View
We view the market's growth quality as increasingly dependent on the conversion of clinical suspicion into reimbursed treatment, rather than on patient awareness alone. Diagnostic capability can enlarge the identifiable population, but durable revenue will accrue most consistently where endocrinology networks, specialty distribution, and payer pathways operate as an integrated care system.
Cushing's Syndrome Diagnostics and Therapeutics Market Segment Analysis
By Category
Within the Cushing's syndrome diagnostics and therapeutics market, the Therapeutics segment generated USD 333.2 million in 2025 and is expected to account for 78.1% of market revenue by 2035. Its position reflects the high value of chronic pharmacologic management and the role of branded glucocorticoid receptor antagonists and steroidogenesis inhibitors in patients who are not adequately managed through surgery alone.
The Diagnostics segment is projected to reach USD 224.0 million by 2035 and is expected to grow at a 9.6% CAGR (2026–2035). Its expansion is tied to broader use of confirmatory cortisol testing, increasing reference-laboratory participation, and the clinical value of reducing ambiguity before initiating specialist therapy.
By Disease Type
Exogenous Cushing's syndrome represented 77.4% of market revenue in 2025 and is projected to generate USD 780.0 million by 2035. The segment's scale stems from the continuing use of pharmacologic glucocorticoids across chronic disease settings and the resulting need to manage treatment-related hypercortisolism.
Endogenous Cushing's syndrome is projected to reach USD 244.0 million by 2035 and is expected to grow at a 9.8% CAGR (2026–2035). Its trajectory is particularly sensitive to gains in biochemical detection, expanded treatment labels, and clinical development activity across pituitary, adrenal, and ectopic disease presentations.
By End Use
Hospitals and clinics generated USD 274.9 million in 2025 and are expected to account for 64.5% of market revenue by 2035. These settings remain central because patients commonly require coordinated endocrine evaluation, imaging, confirmatory testing, treatment selection, and long-term monitoring within specialist care pathways.
Diagnostic centers are projected to reach USD 202.0 million by 2035 and are expected to grow at a 10.2% CAGR (2026–2035). Their growth reflects the decentralization of sophisticated hormone testing into reference laboratory networks that can shorten turnaround times and support earlier treatment decisions.
Homecare settings are projected to generate USD 96.0 million by 2035 and represented 10.0% of market revenue in 2025. Oral therapies and home-based sample collection support this channel, although endocrine oversight and the complexity of biochemical monitoring limit the extent to which care can move fully outside clinical settings.
Other end-use settings generated USD 29.6 million in 2025 and are expected to grow at an 8.3% CAGR (2026–2035). Research organizations, academic institutions, and occupational health programs contribute to testing and clinical-development activity, but their commercial role remains smaller than that of dedicated treatment and diagnostic sites.
GMI Analyst View
We see the most consequential segment shift occurring across the patient episode rather than within a single product category. As diagnostic centers assume more confirmatory testing and hospitals retain complex treatment decisions, market participants that connect assay access, specialist interpretation, and therapy initiation will be better positioned than those serving only one point in the care pathway.
Cushing's Syndrome Diagnostics and Therapeutics Market Regional Analysis
North America Cushing's Syndrome Diagnostics and Therapeutics Market Analysis
The Cushing's syndrome diagnostics and therapeutics market in North America generated USD 169.2 million in 2025 and is expected to hold 38.9% of global revenue by 2035. The region benefits from mature specialist-center networks, established specialty pharmacy infrastructure, and reimbursement systems capable of supporting high-cost rare-disease therapies.
United States
The United States generated USD 153.7 million in 2025 and is expected to represent 34.9% of global market revenue by 2035. Established endocrinology practices, restricted-distribution capabilities, and prior-authorization infrastructure sustain its leading commercial role.
Canada
Canada represented 3.7% of global market revenue in 2025 and is projected to generate USD 40.2 million by 2035. Provincial formulary structures and academic medical centers remain the principal channels through which specialist diagnostics and rare-disease therapies reach patients.
Europe Cushing's Syndrome Diagnostics and Therapeutics Market Analysis
Europe is projected to generate USD 285.7 million by 2035 and represented 28.0% of global market revenue in 2025. National rare-disease programs and organized referral networks support access, although health technology assessment and price-control processes influence the pace of therapy adoption and realized revenue.
Germany
Germany generated USD 23.7 million in 2025 and is projected to reach USD 55.5 million by 2035. Its university hospital system and specialist endocrinology infrastructure support both complex diagnostic workups and access to approved therapies.
UK
The UK represented 4.2% of global market revenue in 2025 and is projected to generate USD 42.5 million by 2035. National referral pathways and specialist centers of excellence provide a structured route to diagnostic confirmation and treatment management.
France
France represented 3.4% of global market revenue in 2025 and is projected to reach USD 34.4 million by 2035. Coordinated rare-disease networks support earlier identification and longitudinal monitoring for patients with complex endocrine disorders.
Italy
Italy represented 2.8% of global market revenue in 2025 and is projected to generate USD 27.9 million by 2035. Access is concentrated in university and research hospital systems where endocrinology expertise and referral capacity are strongest.
Spain
Spain generated USD 9.5 million in 2025 and is expected to grow at a 9.5% CAGR (2026–2035). Broader clinical awareness and continued access to specialist-directed therapies are improving the country's ability to identify and manage patients beyond major metropolitan centers.
Netherlands
The Netherlands represented 1.4% of global market revenue in 2025 and is projected to reach USD 14.9 million by 2035. Concentrated specialist referral infrastructure supports efficient access to advanced diagnostics and endocrine care.
Rest of Europe
Rest of Europe generated USD 35.5 million in 2025 and is projected to reach USD 87.0 million by 2035. Market outcomes vary materially across countries according to reimbursement coverage, rare-disease infrastructure, and specialist availability.
Asia Pacific Cushing's Syndrome Diagnostics and Therapeutics Market Analysis
The Cushing's syndrome diagnostics and therapeutics market in Asia Pacific generated USD 84.6 million in 2025 and is expected to grow at a 10.3% CAGR (2026–2035). Expanding endocrinology capacity, improving access to advanced laboratory testing, and greater regulatory engagement are strengthening the region's patient-identification and treatment infrastructure.
China
China generated USD 13.5 million in 2025 and is expected to grow at a 14.5% CAGR (2026–2035). Local regulatory progress and a growing rare-disease policy focus are expanding the opportunity for approved therapies and associated diagnostic services.
India
India represented 2.0% of global market revenue in 2025 and is projected to generate USD 26.4 million by 2035. Specialist capacity in major urban centers and the expansion of diagnostic laboratory networks are gradually reducing barriers to referral and confirmation.
Japan
Japan represented 3.0% of global market revenue in 2025 and is projected to reach USD 33.0 million by 2035. Its established rare-disease support framework and organized specialist referral system provide a comparatively stable setting for diagnostic and therapeutic uptake.
Australia
Australia generated USD 6.8 million in 2025 and is expected to grow at a 9.2% CAGR (2026–2035). Public hospital endocrinology services and national reimbursement pathways support access once patients receive a confirmed diagnosis.
South Korea
South Korea represented 1.4% of global market revenue in 2025 and is projected to generate USD 16.8 million by 2035. Specialist healthcare infrastructure and advanced endocrinology testing adoption support relatively strong diagnostic intensity.
Rest of Asia Pacific
Rest of Asia Pacific generated USD 37.4 million in 2025 and is expected to represent 7.9% of global market revenue by 2035. Development remains constrained in markets where reimbursement pathways and specialized endocrine services are still emerging.
Latin America Cushing's Syndrome Diagnostics and Therapeutics Market Analysis
Latin America is projected to generate USD 70.7 million by 2035 and represented 7.0% of global market revenue in 2025. Expanding specialist services and selective formulary access are supporting growth, but currency volatility, limited public reimbursement, and urban concentration of care continue to restrict broader adoption.
Brazil
Brazil generated USD 13.3 million in 2025 and is projected to represent 3.2% of global market revenue by 2035. Public high-cost medication programs and private insurance coverage provide differentiated access routes for patients requiring specialized therapies.
Mexico
Mexico represented 2.1% of global market revenue in 2025 and is projected to generate USD 21.6 million by 2035. Private endocrinology practices and evolving coverage arrangements underpin growth, although innovative therapy access remains uneven.
Argentina
Argentina represented 0.9% of global market revenue in 2025 and is projected to reach USD 7.8 million by 2035. Specialist referral concentration supports demand, while import exposure and economic volatility complicate product access and pricing.
Rest of Latin America
Rest of Latin America generated USD 3.8 million in 2025 and is expected to grow at an 8.2% CAGR (2026–2035). Incremental improvements in rare-disease access programs are creating opportunities, but specialized diagnostic and treatment capacity remains limited.
Middle East and Africa Cushing's Syndrome Diagnostics and Therapeutics Market Analysis
The Cushing's syndrome diagnostics and therapeutics market in Middle East and Africa generated USD 21.1 million in 2025 and is expected to represent 4.3% of global market revenue by 2035. Demand is concentrated in Gulf healthcare systems and South African private and academic care settings, while limited specialist density constrains broader regional development.
South Africa
South Africa represented 0.8% of global market revenue in 2025 and is expected to grow at a 7.0% CAGR (2026–2035). Academic hospital services and private insurer coverage remain the principal routes to specialist diagnosis and treatment.
Saudi Arabia
Saudi Arabia represented 1.3% of global market revenue in 2025 and is projected to generate USD 13.3 million by 2035. Public investment in specialized hospital capacity and rare-disease diagnostic infrastructure is strengthening access.
UAE
The UAE is projected to generate USD 10.7 million by 2035 and is expected to grow at a 9.8% CAGR (2026–2035). Specialist centers in Dubai and Abu Dhabi, supported by a proactive healthcare investment environment, provide a foundation for continued market development.
Rest of Middle East and Africa
Rest of Middle East and Africa generated USD 8.4 million in 2025 and is expected to grow at a 5.4% CAGR (2026–2035). Inadequate diagnostic capacity, limited specialist access, and narrow reimbursement coverage for high-cost endocrine therapies continue to moderate demand.
GMI Analyst View
We expect regional differentiation to become more pronounced as Asia Pacific improves identification and treatment infrastructure while North America retains its advantages in reimbursement depth and specialty distribution. The strategic issue is not simply where diagnosis improves fastest, but where that progress can be translated into dependable access to long-term therapy.
Cushing's Syndrome Diagnostics and Therapeutics Market Share & Competitive Landscape
The Cushing's syndrome diagnostics and therapeutics market share is distributed across therapeutic innovators, specialty pharmaceutical suppliers, laboratory platform providers, and diagnostic service organizations. The five leading companies collectively accounted for approximately 35% of market revenue in 2025, underscoring a competitive environment in which clinical differentiation, regulatory execution, specialized distribution, and diagnostic reach matter alongside portfolio scale.
Corcept Therapeutics held approximately 15% of global market share in 2025. Its position is anchored by Korlym and its specialty distribution model, while relacorilant remains commercially relevant as a prospective differentiated cortisol-modulating therapy subject to regulatory resolution.
Recordati held approximately 10% of global market share in 2025. Its Isturisa franchise gained a broader FDA indication for adults with endogenous hypercortisolism when surgery is not an option or has not been curative, strengthening its relevance across a wider clinical population [3]U.S. Food and Drug Administration. "Approval Letter - NDA 212801/S-003, Isturisa (osilodrostat)." accessdata.fda.gov.
Novartis held approximately 5% of global market share in 2025. Its pasireotide portfolio and established rare-disease commercial infrastructure support continued participation in treatment settings where pituitary surgery has failed or cannot be pursued.
Thermo Fisher Scientific participates through laboratory instruments, reagents, and analytical platforms used in cortisol and ACTH workflows. Its competitive importance rests on the installed base and performance expectations of laboratories managing increasingly specialized confirmatory testing.
ESTEVE Pharmaceuticals maintains a therapeutics presence in European markets through steroidogenesis inhibitor offerings. Its regional position is linked to formulary access, clinical familiarity with established agents, and the requirements of country-specific rare-disease treatment systems.
ALPCO, Salimetrics, and DiaMetra contribute assay kits and hormone-testing products used in screening, monitoring, and clinical laboratory workflows. Labcorp provides national reference laboratory capacity for cortisol and ACTH testing in the United States, while Lucichem Pharma, Pfizer, and Teva participate in adjacent therapeutic and generic pharmaceutical categories relevant to the broader treatment landscape.
Cushing's Syndrome Diagnostics and Therapeutics Market Recent Industry Developments
Isturisa Receives Expanded FDA Indication (April 15, 2025): On April 15, 2025, the FDA approved an expanded Isturisa indication covering adults with endogenous hypercortisolism for whom surgery is not an option or has not been curative. The decision broadens the therapy's applicable disease settings beyond Cushing's disease and reinforces Recordati's commercial position in the therapeutic market [3]U.S. Food and Drug Administration. "Approval Letter - NDA 212801/S-003, Isturisa (osilodrostat)." accessdata.fda.gov.
FDA Issues Complete Response Letter for Relacorilant (December 31, 2025): On December 31, 2025, Corcept reported that the FDA issued a Complete Response Letter for relacorilant in hypercortisolism. The company stated that the agency could not reach a favorable benefit-risk conclusion without further evidence of effectiveness, leaving the timing and positioning of a potential launch uncertain [4]Corcept Therapeutics Incorporated. "Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism." ir.corcept.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →